Nektar Therapeutics
ITH
Company Profile
Business description
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Contact
455 Mission Bay Boulevard South
San FranciscoCA94158
USAT: +1 415 482-5300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
61
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,166.70 | 8.80 | 0.11% |
| CAC 40 | 8,022.33 | 20.62 | -0.26% |
| DAX 40 | 22,852.66 | 39.02 | -0.17% |
| Dow JONES (US) | 42,583.32 | 597.97 | 1.42% |
| FTSE 100 | 8,638.01 | 8.78 | -0.10% |
| HKSE | 23,442.29 | 463.27 | -1.94% |
| NASDAQ | 18,188.59 | 404.54 | 2.27% |
| Nikkei 225 | 37,829.76 | 221.27 | 0.59% |
| NZX 50 Index | 12,184.51 | 56.30 | 0.46% |
| S&P 500 | 5,767.57 | 100.01 | 1.76% |
| S&P/ASX 200 | 7,942.50 | 5.60 | 0.07% |
| SSE Composite Index | 3,369.68 | 0.35 | -0.01% |